drugset
drugset / Trial / NCT00425711

Study of Acamprosate in Driving Under the Influence (DUI) Court Participants

NCT00425711 ↗

Terminated 4 enrolled University of Oklahoma Forest Laboratories · collab
NaSingle-groupOpen-labelTreatment

Summary

Acamprosate will be given to approximately 30 DUI Court participants for 3 months and outcomes will be monitored. The hypothesis is that acamprosate will be safe and well-tolerated and that subjects' craving and other symptoms related to addiction will improve over time.

Timeline

Start
2007-02
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Acamprosate Small molecule 333 mg —
Subject Acamprosate Small molecule 666 mg —

Indications

alcohol dependence